XBIT XBiotech Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1626878 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.9%
ROA-29.0%
ROIC (approx.)-193.7%
Asset turnover—
Leverage & solvency
Liabilities / assets3.5%
Debt / equity0.00x
Current ratio39.51x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $0 | $4.01M | $18.39M |
| Cost of revenue | — | — | $0 | $651,000 | $5.82M |
| Gross profit | — | — | $0 | $3.36M | $12.57M |
| R&D expense | $47.39M | $37.76M | $32.85M | $31.54M | $28.27M |
| SG&A expense | $8.29M | $4.71M | $4.66M | $6.30M | $9.39M |
| Operating income | -$55.69M | -$42.47M | -$37.51M | -$34.49M | -$25.08M |
| Pretax income | -$45.30M | -$38.56M | -$24.31M | -$33.59M | -$25.46M |
| Income tax | $235,000 | -$32,000 | $244,000 | -$688,000 | -$8.04M |
| Net income | -$45.54M | -$38.53M | -$24.56M | -$32.90M | -$17.41M |
| EBITDA | -$54.00M | -$40.73M | -$35.81M | -$31.88M | -$22.43M |
| EPS (basic) | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 |
| EPS (diluted) | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 |
| Weighted avg. shares (diluted) | 30.49M | 30.46M | 30.44M | 30.44M | 30.04M |
| Balance sheet | |||||
| Cash & equivalents | $125.55M | $172.68M | $200.02M | $157.31M | $236.98M |
| Short-term investments | — | — | $0 | $60.17M | $0 |
| Receivables | — | $700,000 | $860,000 | $1.22M | $0 |
| Current assets | $126.95M | $174.57M | $201.72M | $219.84M | $246.87M |
| PP&E, net | $23.13M | $24.53M | $24.90M | $26.26M | $28.31M |
| Total assets | $150.08M | $199.09M | $226.62M | $246.10M | $275.18M |
| Current liabilities | $7.93M | $15.11M | $6.10M | $4.07M | $3.45M |
| Total liabilities | $9.73M | $16.82M | $7.77M | $5.70M | $5.79M |
| Shareholders' equity | $140.35M | $182.27M | $218.85M | $240.40M | $269.38M |
| Shares outstanding | 30.49M | 30.49M | 30.44M | 30.44M | 30.44M |
| Cash flow statement | |||||
| Operating cash flow | -$39.92M | -$30.96M | -$18.73M | -$14.82M | $69.44M |
| Capital expenditure | $289,000 | $1.30M | $362,000 | $585,000 | $3.52M |
| Free cash flow | -$40.21M | -$32.27M | -$19.09M | -$15.41M | $65.92M |
| Investing cash flow | -$289,000 | -$1.30M | $61.50M | -$63.89M | -$3.52M |
| Financing cash flow | -$10.25M | $10.45M | -$9,000 | $0 | -$67.01M |
| Depreciation & amortization | $1.69M | $1.75M | $1.70M | $2.61M | $2.65M |
| Stock-based compensation | $3.62M | $1.75M | $3.26M | $5.06M | $4.46M |
| Dividends paid | — | — | — | $0 | $75.00M |
| Share buybacks | — | $0 | $14,000 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.